Valbiotis Future Growth

Future criteria checks 2/6

Valbiotis is forecast to grow earnings and revenue by 59.3% and 85.3% per annum respectively while EPS is expected to grow by 35.6% per annum.

Key information

59.3%

Earnings growth rate

35.6%

EPS growth rate

Biotechs earnings growth	43.0%
Revenue growth rate	85.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	30 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:8JD - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	8	-4	-13	-11	1
12/31/2025	18	3	-2	-3	2
12/31/2024	0	-12	-8	-8	1
6/30/2024	1	-9	-8	-7	N/A
3/31/2024	3	-8	-8	-8	N/A
12/31/2023	5	-7	-8	-8	N/A
9/30/2023	5	-8	-9	-9	N/A
6/30/2023	4	-9	-10	-10	N/A
3/31/2023	3	-11	-10	-10	N/A
12/31/2022	1	-12	-9	-9	N/A
9/30/2022	1	-11	-10	-9	N/A
6/30/2022	1	-10	-10	-9	N/A
3/31/2022	1	-9	-9	-8	N/A
12/31/2021	0	-9	-8	-7	N/A
9/30/2021	2	-7	-6	-6	N/A
6/30/2021	3	-4	-4	-4	N/A
3/31/2021	3	-4	-1	-1	N/A
12/31/2020	3	-4	2	3	N/A
9/30/2020	2	-5	2	2	N/A
6/30/2020	0	-6	1	2	N/A
3/31/2020	0	-6	-2	-2	N/A
12/31/2019	0	-6	-5	-5	N/A
9/30/2019	0	-6	-6	-5	N/A
6/30/2019	0	-6	-6	-6	N/A
3/31/2019	0	-5	-6	-5	N/A
12/31/2018	0	-5	-5	-5	N/A
9/30/2018	0	-4	-5	-4	N/A
6/30/2018	0	-4	-5	-4	N/A
3/31/2018	0	-3	N/A	-3	N/A
12/31/2017	0	-2	N/A	-2	N/A
9/30/2017	0	-2	N/A	N/A	N/A
6/30/2017	0	-1	N/A	N/A	N/A
3/31/2017	0	-1	N/A	N/A	N/A
12/31/2016	N/A	-1	N/A	-1	N/A
12/31/2015	0	0	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8JD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8JD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8JD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 8JD's revenue (85.3% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: 8JD's revenue (85.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 8JD's Return on Equity is forecast to be high in 3 years time

Valbiotis Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2023

Recent updates

New minor risk - Profitability

New major risk - Share price stability

Valbiotis SA, Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released

New minor risk - Shareholder dilution

New minor risk - Profitability

Valbiotis SA has filed a Follow-on Equity Offering in the amount of €15.000001 million.

Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance

Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released

Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure

Forecast breakeven date pushed back to 2024

Valbiotis SA announced that it has received €9.7 million in funding

Valbiotis SA Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia

First half 2022 earnings released

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Announces Completion of Recruitment for the Phase Ii/Iii Reverse-It Clinical Study with Totum•63 Against Prediabetes, in Partnership with Nestlé Health Science

Valbiotis Announces the Major Success of the Phase II Heart Clinical Study the Patented Plant-Based Active Substance Totum•070 Proves Its Efficacy Against Hypercholesterolemia, A Cardiovascular Risk Factor

No independent directors

Valbiotis SA Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia

Full year 2021 earnings: Revenues miss analyst expectations

Valbiotis Announces Board of Directors Changes

Valbiotis SA to Report Fiscal Year 2021 Results on Mar 15, 2022

Valbiotis Announces Approval to Launch the Two Phase II/III Insight and Insight 2 Clinical Studies, the Last Step in the Development of Totum•854 for the Reduction of Blood Pressure

Forecast to breakeven in 2023

Valbiotis Submits to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents its Comprehensive Clinical Development Plan

First half 2021 earnings released

Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action

Full year 2020 earnings released

Valbiotis SA to Report First Half, 2021 Results on Sep 30, 2021

Valbiotis Selected to Present TOTUM-854 Results on Arterial Hypertension

Valbiotis SA Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021

Valbiotis Authorizes to Launch Heart, the Phase II Multi-Center Clinical Study with TOTUM-070, for the Reduction of Blood LDL-Cholesterol Levels

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies